Answers are grounded in this paper and cite their sources.
Xevinapant, a drug previously under development for head and neck cancer, was investigated to determine its intrinsic clearance (CLint) in vitro and assess the involvement of CYP enzymes in its metabolism. Extensive in vitro studies showed very low turnover, necessitating advanced methodologies to accurately measure CLint values.2. Two novel in vitro assays, using a modified suspension hepatocyte protocol or 3D hepatocyte spheroid cultures, allowed measuring hepatic turnover of xevinapant with very low CLint values of 1.3 or 0.3 µL/min/106 cells, respectively. Reaction phenotyping using specific inhibitors, enabled by enhanced detection capabilities in spheroids, identified primarily CYP3A (> 50%) as contributor to the hepatic metabolism of xevinapant.3. In vitro-in vivo extrapolation, in combination with data from the human mass balance study, revealed that hepatic metabolism, primarily mediated by CYP3A, accounts for approximately 30% of the overall clearance. The remaining clearance is renal (∼20%) and metabolic, but potentially extrahepatic (∼50%).4. This research highlights the importance and benefits of utilizing advanced in vitro techniques, such as human hepatocyte spheroids, to accurately characterize drug metabolism, providing valuable insights for pharmacokinetic evaluations and, ultimately, supporting the development of a PBPK model and understanding the DDI risk of xevinapant.
No takes yet. Share an insight, caveat, or question.
Jacob et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: